1. Scrip
  2. >>Focus On Asia

Sequella CEO Carol Nacy On Partnering With Pfizer To Solve Multidrug-resistant TB

 
• By Tamra Sami

New drugs in development could help solve a looming global multidrug-resistant TB epidemic and anchor a new treatment regimen.

Sequella Inc. CEO Carol Nacy sees the company’s recent in-licensing deal with Pfizer as a turning point in the long road to developing anti-infectives to treat multidrug-resistant tuberculosis, and is gearing up for pivotal trials in 2014.

Nacy founded Sequella in 1997 to address the looming TB encroachment. Lead drug SQ109 was co-discovered by scientists at Sequella...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

Shigella Vaccine Pipeline And Why It Matters

 
• By Vibha Ravi

A GSK-Bharat Biotech deal on a shigella vaccine candidate has cast a spotlight on the disease which is the second leading cause of diarrheal deaths in children below five. Scrip looks at data from Pharmaprojects, WHO and other sources to highlight why a vaccine matters and what pharma is doing

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: US policies in spotlight at BIO; Lilly’s Verve acquisition; UroGen’s bladder cancer approval; Ireland’s biopharma talent; and Korea proposes new AI R&D project.

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC

 
• By Joseph Haas, Lisa Takagi, Sushmita Panda, and Xu Hu

Axcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.